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Signal transducers and activators of transcription
(STATs) are a family of latent cytoplasmic transcrip-
tion factors that transmit signals from the cell mem-
brane to the nucleus. One family member, STAT3, is
constitutively activated by aberrant upstream tyrosine
kinase activities in a broad spectrum of cancer cell
lines and human tumors. Screening of chemical librar-
ies led to the identification of Stattic, a nonpeptidic
small molecule shown to selectively inhibit the func-
tion of the STAT3 SH2 domain regardless of the
STAT3 activation state in vitro. Stattic selectively in-
hibits activation, dimerization, and nuclear transloca-
tion of STAT3 and increases the apoptotic rate of
STAT3-dependent breast cancer cell lines. We pro-
pose Stattic as a tool for the inhibition of STAT3 in
cell lines or animal tumor models displaying constitu-
tive STAT3 activation.
Introduction
Upon activation of cytokine receptors or growth factor
receptors, STATs are recruited via their SH2 domains
and phosphorylated on a tyrosine residue adjacent to
the SH2 domain by receptor-associated tyrosine ki-
nases or the intrinsic kinase activity of growth-factor
receptors [1]. STATs can also be phosphorylated by
constitutively active nonreceptor tyrosine kinases (e.g.,
v-Src). Tyrosine-phosphorylated STATs form homo- or
heterodimers via reciprocal phosphotyrosine (pTyr)-
SH2 interactions and translocate to the nucleus, where
they bind to their respective DNA-binding motifs within
the promoter elements of target genes and induce tran-
scription. Since the SH2 domain is required for both ty-
rosine-phosphorylation and dimerization of STATs, the
most logical approach toward inhibition of any STAT, in-
cluding STAT3, would impair the function of its SH2 do-
main [2]. This should not only inhibit STAT3 activation
but also prevent dimerization of any STAT3 molecules
that escape inhibition of activation (Figure 1). Direct inhi-
bition of STAT3 itself is also less likely to result in unin-
tentional inhibition of additional signaling pathways
than the targeting of upstream molecules. While the
principle feasibility to inhibit STAT3 in cells by a ligand
for its SH2 domain has been demonstrated with fusion
*Correspondence: berg@biochem.mpg.depeptides carrying hydrophobic or basic peptide se-
quences to achieve cell permeability [3, 4] and a peptide-
derived molecule [5], the nature of these agents required
their use at relatively high concentrations in tissue cul-
ture, and their conversion to nonpeptidic molecules is
likely to be difficult.
STAT3 has received particular attention among the
seven members of the STAT family since it is considered
a candidate target for the treatment of human tumors [6,
7]. It is constitutively activated by aberrant upstream ty-
rosine kinase activities in a broad spectrum of cancer
cell lines and human tumors [8, 9]. Inhibition of STAT3
signaling by a dominant-negative mutant [10, 11], anti-
sense approaches [12], decoy oligonucleotides [13–
15], siRNAs [16–18], or G-quartet oligonucleotides [19,
20] has been demonstrated to suppress tumor growth
and to induce apoptosis in cancer cells. While numerous
small molecules have been reported to inhibit STAT3
signaling, the vast majority of them act on targets other
than STAT3. STAT3 signaling inhibitors with unknown
targets [21, 22] include members of the cucurbitacin
family of natural products [23–25]. A recent study sug-
gested that the JAK/STAT3 pathway inhibitor cucurbita-
cin I also affected the actin cytoskeleton in nontumor
cells [26]. Curcumin, another indirect natural product in-
hibitor of STAT3 signaling [27], has also been identified
as an inhibitor of numerous additional signaling path-
ways [28]. Similarly, magnolol was shown to inhibit sig-
naling via STAT3 and other pathways [29]. In addition
to these inhibitors with unknown targets, a number of
natural products have been shown to inhibit kinases up-
stream of STAT3. They include indirubin, a constituent of
a Chinese herbal prescription used for treatment of
chronic myelogenous leukemia [30], and a known inhib-
itor of cyclin-dependent kinases [31], which was shown
to inhibit STAT3 signaling in breast cancer cells by inhib-
iting upstream kinase activity, presumably that of c-Src
[32]. A similar mechanism of action was suggested for
the natural product Resveratrol [33]. Flavopiridol, a cyto-
toxic compound with several identified targets, was
shown to inhibit STAT3 signaling, presumably by inter-
calation into DNA [34]. Among the small molecules that
are thought to bind to STAT3 directly, galiellalactone,
a natural product with weak activity against the de
novo synthesis of a-amylases, proteases, and phospha-
tases in embryoless halves of wheat seeds [35], was re-
ported to inhibit interleukin-6 (IL-6)-mediated STAT3
signaling [36]. The compound was assumed to bind to
the DNA-binding domain of dimeric STAT3, possibly
by covalently modifying a cysteine residue in the
STAT3 DNA-binding domain. A similar mechanism of ac-
tion was discussed for a platinum complex that was re-
ported to bind to STAT3 and to inhibit STAT3 signaling
[37]. Other platinum complexes were also reported to in-
hibit STAT3 signaling [38].
To date, the only report of a nonpeptidic small-mole-
cule reported to inhibit STAT3 by direct binding to its
SH2 domain used virtual screening to identify candidate
compounds with an increased likelihood of binding to
the STAT3 SH2 domain. One of these compounds,
Chemistry & Biology
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STAT3 SH2 Domain Would Selectively and
Effectively Inhibit STAT3 Functions
A substance that blocks the function of the
STAT3 SH2 domain would inhibit binding of
STAT3 to activated cell surface receptors
(e.g., the IL-6 receptor) and constitutively
activated tyrosine kinases (e.g., v-src) (inhi-
bition mechanism A, inhibition is indicated
by t) and also inhibit dimerization of STAT3
molecules that escape inhibition of phos-
phorylation (inhibition mechanism B) and
could therefore be a particularly efficient
inhibitor.STA-21, was shown to inhibit DNA binding of prephos-
phorylated STAT3 and to display STAT3-dependent cel-
lular effects [39]. While STA-21 could be docked into the
STAT3 SH2 domain [40] by computational methods,
biochemical experiments that demonstrate its effective-
ness against the function of the SH2 domain of unphos-
phorylated STAT3 in vitro, or its effect on STAT3 phos-
phorylation of serum-deprived cells in response to
cytokine stimulation, were not provided. Here, we report
the discovery of Stattic, to our knowledge the first non-
peptidic small molecule demonstrated to inhibit the
function of the STAT3 SH2 domain regardless of the
STAT3 phosphorylation state in vitro. Stattic selectively
inhibits activation, dimerization, and nuclear transloca-
tion of STAT3 and induces apoptosis in STAT3-depen-
dent cancer cell lines.
Results and Discussion
Screening of chemical libraries consisting of a diverse
collection of 17,298 substances in a fluorescence polar-
ization-based binding assay [41] resulted in the identifi-
cation of 144 substances that inhibited binding of a fluo-
rescein-labeled, phosphotyrosine-containing peptide to
the STAT3 SH2 domain by more than 60%. One of these
substances was able to inhibit interleukin-6 (IL-6)-in-
duced nuclear translocation of STAT3 as assessed by
immunolocalization and to inhibit DNA binding of pre-
phosphorylated STAT3 in electrophoretic mobility shift
assays (EMSA) with selectivity over STAT1. This com-
pound, 6-nitro-benzo[b]thiophene-1,1-dioxide 1 (Fig-
ure 2A), was dubbed Stattic (for STAT three inhibitory
compound, and based on its ability to retain STAT3 in
the cytosol). Stattic inhibited binding of a phosphotyro-
sine-containing peptide derived from the gp130 recep-tor to the STAT3 SH2 domain in a strongly tempera-
ture-dependent manner: while only weak activity was
observed at 22C, the compound displayed moderate
activity at 30C and high potency at the physiologically
relevant temperature of 37C (apparent IC50 value after
1 hr of incubation: 5.1 6 0.8 mM) (Figure 2B). Stattic
only had a very weak effect on binding of a tyrosine-
phosphorylated peptide to the SH2-domain of the tyro-
sine kinase Lck (Figure 2C). Dimerization of two other
dimeric transcription factors (c-Myc/Max and Jun/Jun)
was not significantly inhibited [42]. Further specificity
analysis involving the protein family members STAT1
and STAT5b was performed at an intermediate temper-
ature of 30C since the limited thermal stability of the
STAT1 and STAT5b proteins expressed from E. coli pro-
hibited analysis at 37C. Reduced inhibition of the SH2
domains of STAT1 (78% similar) and STAT5b (59% sim-
ilar) by Stattic correlated well with the degree of similar-
ity in the SH2 domains between the respective proteins
and STAT3 (Figure 2D). Analysis of structure-activity re-
lationships of Stattic and three related compounds per-
formed at 37C revealed the importance of the nitro
group since its exchange by an NH2-group in compound
2 or by hydrogen in compound 3 (Figure 2A) resulted in
loss of activity in the fluorescence polarization assay
(2, 8% 6 4%; 3, 18% 6 5% inhibition at 100 mM after
1 hr of incubation). Both compounds 2 and 3 were part
of the screening library but were not registered as hits
due to their low activities. A similar loss in activity was
observed when the double bond of the vinyl sulfone moi-
ety was saturated (compound 4, 12%6 2% inhibition at
100 mM after 1 hr of incubation) (Figure 2A).
The temperature dependence of the inhibition, in
combination with the observed importance of the dou-
ble bond conjugated to the sulfonyl group, led us to
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1237Figure 2. Stattic Selectively Inhibits STAT3
In Vitro
(A) Structure of Stattic (1) and inactive deriv-
atives 2–4.
(B) Temperature dependence of the inhibition
of binding between 5-carboxyfluorescein-
GY(PO3H2)LPQTV-NH2 and STAT3 by Stattic
assayed by fluorescence polarization. Error
bars represent standard deviations (SD).
(C) Inhibition of binding of fluorescein-la-
beled phosphopeptides to the SH2 domains
of STAT3 and Lck and of fluorescein-labeled
oligonucleotides to c-Myc/Max and Jun/Jun
dimers, by Stattic at 37C assayed by fluo-
rescence polarization. The inhibition curve
for c-Myc/Max is masked by the inhibition
curve for Lck. Error bars represent SD.
(D) Inhibition of binding of fluorescein-la-
beled phosphopeptides to the SH2 domains
of STAT3, STAT1, and STAT5b by Stattic at
30C assayed by fluorescence polarization.
Error bars represent SD.
(E) Time dependence of the inhibition of bind-
ing between 5-carboxyfluorescein-GY
(PO3H2)LPQTV-NH2 and STAT3 by Stattic at
37C assayed by fluorescence polarization.
Error bars represent SD.investigate whether inhibition by Stattic was irreversible.
Inhibition of Stat3 was in fact time dependent, which
pointed toward an irreversible mode of action (Fig-
ure 2E). The observation that Stattic’s activity was
strongly reduced in the presence of 2 mM dithiothreitol
(DTT) in the fluorescence polarization assay buffer can
be explained by a nucleophilic attack of DTT on Stattic
(data not shown). The presence or absence of DTT in
the fluorescence polarization assay buffer had no signif-
icant effect on the STAT3 assay (see Figure S1 available
with this article online). Final evidence for a covalent
modification of STAT3 by Stattic could for example arise
from the identification of modified residues via mass
spectrometry-based approaches. While it is tempting
to speculate that such modified residues are nucleo-
philic amino acids within or near the STAT3 SH2 domain,
which are covalently modified in a Michael addition,
initial attempts to identify such an amino acid by mass
spectrometry have remained inconclusive.Electrophoretic mobility shift assays (EMSA) per-
formed at 37C using nuclear extracts from EGF-stimu-
lated cells, which contain prephosphorylated STAT3
and STAT1, demonstrated inhibition of DNA binding of
STAT3 homodimers by Stattic at a concentration of 10
mM, while binding of STAT1 homodimers to the same
DNA probe was not significantly inhibited at concentra-
tions of up to 200 mM (Figure 3, left panel). Control com-
pounds 2–4 did not significantly inhibit DNA binding of
STAT dimers at concentrations of 100 and 200 mM (Fig-
ure 3, right panel). A potential explanation for the signif-
icantly enhanced selectivity of Stattic for STAT3 over
STAT1 in EMSA, as compared to the fluorescence polar-
ization assay (see Figure 2D), is that the observed activ-
ity profile in the fluorescence polarization assay at 30C
does not reflect the activity profile at the physiologically
relevant temperature of 37C.
Specific cellular activity is a key requisite for the suit-
ability of any interfering agent as a research tool. ToFigure 3. Stattic Inhibits STAT3 Dimerization and DNA Binding In Vitro
Inhibition of STAT3 homodimerization and DNA binding, but not STAT1 homodimerization and binding to the same DNA probe, in EMSA by
Stattic at 37C (left panel). Control compounds 2–4 do not significantly inhibit DNA binding of STAT dimers at 100 and 200 mM (right panel).
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1238Figure 4. Stattic Selectively Inhibits STAT3 Activation and Nuclear Translocation in HepG2 Cells
(A) Stattic was added to the media of serum-deprived HepG2 cells 1 hr prior to stimulation by IL-6 (for STAT3) or IFN-g (for STAT1). Upon cell
lysis, phosphorylation of STAT3 Tyr705 and STAT1 Tyr701 was analyzed by western blot.
(B) Cells were treated as in (A), but instead of whole-cell lysates, nuclear lysates were prepared and analyzed in EMSA by using the same DNA
probe for both STAT3 and STAT1.
(C) Serum-deprived HepG2 cells grown on 16-well Nunc LabTek slides were incubated with Stattic and compounds 2–4 for 1 hr prior to cos-
timulation by IL-6 and IFN-g. Cells were fixed, permeabilized, and stained for STAT3 and STAT1.investigate Stattic’s suitability as a tool for the analysis
of STAT3 biological functions in vivo, we tested it in
two unrelated cellular assay systems. HepG2 liver carci-
noma cells were induced with either IL-6, leading to se-
lective phosphorylation of STAT3 at Tyr705, or IFN-g, for
selective activation of STAT1 at Tyr701, as a stringent
specificity control. Analysis of the tyrosine phosphoryla-
tion states revealed that preincubation of serum-starved
HepG2 cells with 20 mM of Stattic led to a selective
reduction of phosphorylation of STAT3 Tyr705, while
activation of STAT1 Tyr701 remained unchanged (Fig-
ure 4A). The inactivity of the derivatives 2–4 in this assay
correlated well with their lack of activity in vitro (data not
shown). EMSA performed on nuclear lysates obtained
from starved HepG2 cells preincubated with 20 mM of
Stattic and subsequently stimulated with IL-6 and IFN-g
showed that STAT3 DNA-binding activity had been
lost, while STAT1 DNA binding was not inhibited (Fig-
ure 4B). Since tyrosine phosphorylation and dimeriza-
tion of STATs is a prerequisite for their cytokine-induced
nuclear translocation, we would expect a selectiveSTAT3 SH2 domain inhibitor to inhibit IL-6-induced
STAT3 nuclear translocation, but not IFN-g-induced
STAT1 translocation. Accordingly, immunofluorescence
microscopy showed that cytokine-induced nuclear
translocation of STAT3 was inhibited after preincubation
with 20 mM of Stattic, while the corresponding STAT1
translocation was only minimally affected. Consistent
with the previous results, derivatives 2–4 were inactive
in this assay (Figure 4C).
The breast cancer cell lines MDA-MB-231 and MDA-
MB-435S display constitutive phosphorylation of STAT3
Tyr705 and have been reported to undergo apoptosis
upon inhibition of STAT3 signaling by small molecules
[25, 37, 38]. In contrast, MDA-MB-453 breast cancer cells
do not show elevated STAT3 pTyr705 levels and do not
enter apoptosis by inhibition of STAT3 signaling. West-
ern blot analysis revealed that phosphorylation of
STAT3 Tyr705 is reduced in MDA-MB-231 and MDA-
MB-435S cells in the presence of 10 or 20 mM Stattic
(Figure 5A). The activation state of the tyrosine kinases
JAK1, JAK2, and c-Src, which are considered to be
STAT3 Inhibitor
1239Figure 5. Stattic Selectively Induces Apoptosis in STAT3-Dependent Breast Cancer Cell Lines
(A) MDA-MB-231 and MDA-MB-435S cells were treated with Stattic for 2 hr at the indicated concentrations. The activation state of STAT3,
STAT3-activating kinases, and other signaling molecules was analyzed by western blot analysis of whole-cell lysates with phospho-specific
antibodies.
(B) Incubation with 10 mM Stattic for 24 hr induces apoptosis in STAT3-dependent breast cancer cell lines MDA-MB-231 and MDA-MB-435S,
but not in STAT3-independent MDA-MB-453 cells, as judged by the sub-G1 peak obtained by flow cytometry. Error bars represent SD.
(C) Incubation with 10 mM Stattic for 24 hr induces apoptosis in the STAT3-dependent breast cancer cell line MDA-MB-435S, but not in STAT3-
independent MDA-MB-453 cells, as judged by TUNEL assay.
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not significantly inhibited by the presence of 10 or 20
mM Stattic, as judged by western blot analysis using
phospho-specific antibodies against tyrosine residues
that are thought to be autophosphorylated by the re-
spective kinases themselves. This is consistent with
the idea that the compound exerts its cellular effects
by preventing the activating kinases from binding to
the STAT3 SH2 domain, without interfering with their en-
zymatic activities. The basal activation states of other
signaling pathways were not significantly inhibited.
Flow cytometry-based analysis of cell lysates treated
with 10 mM of Stattic showed a 7.6-fold increase in the
sub-G1 population induced in the STAT3-dependent
MDA-MB-231 cells, and even a 14.4-fold increase in
MDA-MB-435S cells. In contrast, only a slight increase
(1.7-fold) in the sub-G1 population was induced in the
STAT3-independent MDA-MB-453 cells, suggesting
the induction of apoptosis in a STAT3-dependent man-
ner (Figure 5B). The minor induction of apoptosis in
MDA-MB-453 cells might perhaps be due to reactive
oxygen species (ROS), which have been reported to be
caused by some related benzo[b]thiophenesulphona-
mides [43, 44]. Consistent with these results, terminal
deoxynucleotidyl transferase-mediated nick end label-
ing (TUNEL) revealed significant apoptosis in MDA-MB-
435S cells after treatment with 10 mM Stattic for 24 hr
(Figure 5C) and, to lesser extent, in MDA-MB-231 cells
(data not shown), whereas no significant change in the
apoptotic rate could be observed in MDA-MB-453 cells
(Figure 5C).
The tight temporal control of the inhibition of STAT3
by Stattic (see Experimental Procedures for the immu-
nofluorescence assay shown in Figure 4) could make
Stattic an attractive tool for the analysis of STAT3 func-
tions that were hitherto impossible to perform in genet-
ically unmodified systems. For example, Stattic could be
used for the analysis of STAT3 functions within a given
phase of the cell cycle of synchronized cell populations
or for the analysis of immediate-early responses in gene
regulation of STAT3-dependent cancer cells upon inac-
tivation of STAT3. Hence, inhibition of STAT3 by Stattic
could complement siRNA-based approaches toward
depletion of STAT3, the temporal control of which is lim-
ited by the half-life time of the pre-existing STAT3 mole-
cules (8.5 hr) [45]. Moreover, Stattic should be widely
applicable in studying the functions of STAT3 in cellular
systems and animal models, especially those that
display constitutive activation of STAT3.
Significance
The transcription factor STAT3 is constitutively acti-
vated in most human tumors. Inhibition of STAT3 sig-
naling has been demonstrated to increase the apopto-
tic rate of STAT3-dependent tumor cells. Since the
function of the STAT3 SH2 domain is crucial for both
STAT3 activation and nuclear translocation, STAT3
signaling can be inhibited by small molecules that im-
pair the function of the STAT3 SH2 domain. Using
high-throughput screening of diverse chemical librar-
ies, we have identified Stattic, to our knowledge the
first nonpeptidic small molecule demonstrated to se-
lectively inhibit the function of the STAT3 SH2 domainregardless of the STAT3 activation state in vitro. Stat-
tic inhibits binding of a physiologically relevant tyro-
sine-phosphorylated peptide motif to the STAT3 SH2
domain and inhibits dimerization and DNA binding of
STAT3 with selectivity over the inhibition of its family
member STAT1. It potently and selectively inhibits
STAT3 activation and nuclear translocation, and se-
lectively induces apoptosis of STAT3-dependent can-
cer cell lines. Stattic thus reveals itself as a potentially
useful tool for the inhibition of STAT3 activation and
activity and for the disruption of aberrantly high
STAT3 activity in cancer cell lines and tumor models.
The data presented should encourage the scientific
community to explore the development of cancer
drugs that act by inhibition of the SH2 domain of
STAT3. The current perception that ‘‘druggable’’ pro-
teins are generally restricted to enzymes and recep-
tors should thus be reconsidered.
Experimental Procedures
Antibodies
The following antibodies were used: rabbit anti-STAT3 pTyr705, rab-
bit anti-STAT1 pTyr701, rabbit anti-STAT1 (for western blots), rabbit
anti-JAK2 (pTyr1007/pTyr1008), rabbit anti-p44/p42 MAP kinase
(Thr202/Tyr204), rabbit anti-JNK (pThr183/pTyr185), and rabbit
anti-pAkt (pSer473) from Cell Signaling; rabbit pJAK1 (pTyr1022/
pTyr1023) from BioSource; rabbit anti-STAT3, rabbit anti-src, rabbit
anti-JNK1, rabbit anti-ERK1/2, and rabbit anti-Akt1/2 from Santa
Cruz; rabbit anti-JAK2 from Upstate; mouse anti-JAK1 and mouse
anti-STAT1 (for immunofluorescence) from BD Biosciences; and
rabbit anti-actin and mouse anti-tubulin from Sigma. Secondary
horseradish peroxidase (HRP)-conjugated antibodies were from
DakoCytomation. Secondary Alexa Fluor 488 goat anti-rabbit anti-
body and Alexa Fluor 546 goat anti-mouse IgG1 antibody were
from Molecular Probes.
Chemical Substances
Compounds 1–3were purchased from Maybridge. Compound 4was
synthesized by catalytic hydrogenation of 1 as described in the Sup-
plemental Data available online.
High-Throughput Screening and Fluorescence
Polarization Assays
8,298 compounds from Chemical Diversity and 9,000 compounds
from Maybridge were tested in a fluorescence polarization assay
that analyzes binding of small molecules to the STAT3 SH2 domain.
Screening was performed at approximately 30C. The specificity of
screening hits was validated in analogous assays for binding of the
test compounds to the SH2 domains of STAT1 [46], STAT5, and Lck
[41]. The final concentration of buffer components used for all FP as-
says was 10 mM HEPES (pH 7.5), 1 mM EDTA, 0.1% Nonidet P-40, 50
mM NaCl, and 10% DMSO. The absence of dithiothreitol is essential
for inhibitory activity. The sequences of the peptides were: STAT3,
5-carboxyfluorescein-GY(PO3H2)LPQTV-NH2; STAT1, 5-carboxy-
fluorescein-GY(PO3H2)DKPHVL; STAT5, 5-carboxyfluorescein-GY
(PO3H2)LVLDKW; and Lck, 5-carboxyfluorescein-GY(PO3H2)EEIP.
Peptides were >95% pure. For specificity analysis at 30C, proteins
were used at 150 nM (STAT1, STAT3, and STAT5). For specificity
analysis at 37C, proteins were used at 370 nM (STAT3) or 100 nM
(Lck). Proteins were incubated with test compounds in Eppendorf
tubes at the indicated temperatures for 60 min prior addition of the
respective 5-carboxyfluorescein labeled peptides (final concentra-
tion: 10 nM). Analysis of c-Myc/Max and Jun/Jun dimerization and
DNA binding at 37C was performed as described [42], but in the
absence of DTT. Before measurement at room temperature, the mix-
tures were allowed to equilibrate for at least 30 min. Test com-
pounds were used at the indicated concentrations diluted from
a 203 stock in DMSO. Binding curves and inhibition curves were fit-
ted with SigmaPlot (SPSS Science Software GmbH). All competition
curves were repeated three times in independent experiments. For
STAT3 Inhibitor
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were mixed from stock solutions kept at 0C and then incubated
at 37C. Aliquots were taken at the indicated time points.
Electrophoretic Mobility Shift Analysis
To obtain the prephosphorylated STAT proteins used in Figure 3,
NIH3T3 cells stably transformed with the EGF receptor were stimu-
lated with 100 ng/ml EGF for 10 min, and nuclear lysates were pre-
pared essentially as described [47]. Three microliters of nuclear pro-
tein (approximately 8 mg/ml) was added to 2 ml of 53 binding buffer
(65 mM HEPES [pH 7.9], 0.75 mM EDTA, 40% glycerol), 1 ml test com-
pound dissolved in DMSO from a 103 stock, and 1 mg of poly(dI-dC)
(Roche Applied Science). For competition binding assays, unlabeled
oligonucleotide was added to the reaction in 1000-fold molar ex-
cess. For a supershift control, 1 mg anti-STAT3 antibody or 1 mg
anti-STAT1 antibody was added to the reaction mixtures. Total reac-
tion volume was 10 ml. All reactions were incubated at 37C for 2 hr
prior to addition of the [g-32P]ATP-labeled oligonucleotides (upper
strand sequence: [hSIE], 50-AGCTTCATTTCCCGTAAATCCCTA-30)
for 20 min at room temperature. Protein-DNA complexes were re-
solved on a 4% acrylamide gel (45 mM Tris-borate, 1 mM EDTA),
and gels were dried before autoradiography. To assess the effect
of the test compounds on STAT phosphorylation as shown in Fig-
ure 4B, HepG2 cells were treated with compound for 1 hr (final
DMSO concentration of 1%) and then stimulated with 50 ng/ml IL-
6 for 30 min (for STAT3) or 50 ng/ml IFN-g for 15 min (STAT1). Nuclear
lysates were prepared essentially as described [36] and incubated
with the hSIE oligonucleotides as outlined above. As controls, 1 mg
anti-STAT3 antibody, 1 mg anti-STAT1 antibody, 1 mg anti-Src anti-
body, five molar equivalents of unlabeled hSIE oligonucleotides or
mutated hSIE oligonucleotides (50-AGCTTCATTTCCCTTAAATCCC
TA-30) were added to the respective reaction mixtures.
Immunofluorescence Assay
HepG2 cells were grown in 16-well LabTek slides (Nunc) and sub-
jected to serum-free MEM medium for 24 hr. After incubation with
the indicated concentration of compound for 1 hr at a final DMSO
concentration of 1%, cells were stimulated with 50 ng/ml IL-6 and
50 ng/ml IFN-g for 40 min. Cells were fixed with 4% paraformalde-
hyde for 10 min and permeabilized for 10 min with 1% Triton
X-100 in PBS. After blocking with 1% goat serum, simultaneous in-
cubation with antibodies against STAT3 and STAT1 for 1 hr was fol-
lowed by simultaneous incubation with both secondary antibodies
for 1 hr. Cells were counterstained with DAPI. Cells were imaged
by confocal microscopy at 403 magnification.
Analysis of Apotosis by Flow Cytometry
MDA-MB-231, MDA-MB-435S, and MDA-MB-453 cells were seeded
at 53 104 cells in 6-well plates (Corning), grown for 24 hr before add-
ing DMSO or Stattic (final DMSO concentration 0.1%), and then incu-
bated with the inhibitor for 24 hr. All cells were collected and resus-
pended in buffer (0.1% sodium citrate, 0.1% Triton X-100, 20 mM
propidium iodide) and incubated for 3 hr before 104 cells per sample
were analyzed by flow cytometry with a FACSCalibur (BD Biosci-
ences) equipped with a 488 nm laser.
Analysis of Apotosis by TUNEL
MDA-MB-231, MDA-MB-435S, and MDA-MB-453 cells were seeded
in 16-well LabTek slides (NUNC) at 4,000 cells per well and allowed
to grow for 24 hr. The cells were then incubated with either 1%
DMSO, 10 mM Stattic, or 10 mM doxorubicin for an additional 24 hr.
Cells were washed with PBS, fixed with 4% paraformaldehyde in
PBS at room temperature for 60 min, and permeabilized with 0.1%
Triton X-100 and 0.1% sodium citrate in PBS for 2 min on ice. DNA
strand breaks were visualized by using the In Situ Cell Death Detec-
tion Kit, Fluorescein (Roche) following the manufacturer’s instruc-
tions. Cells were then stained with DAPI. The slides were mounted
with a coverslip by using Fluoromount G. Pictures were taken on
a Zeiss Axioplan 2 imaging microscope with 403 magnification.
Supplemental Data
Supplemental Data describing the synthesis of compound 4, one
experimental figure, tissue culture conditions, and western blotanalysis are available online at http://www.chembiol.com/cgi/
content/full/13/11/1235/DC1/.
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